Please login to the form below

Not currently logged in
Email:
Password:

GSK's Q3 sales grow 3 per cent

GlaxoSmithKline recorded a growth in sales of 3 per cent in its financial results for the third quarter of 2011, as net income remained level

GlaxoSmithKline (GSK) has recorded a growth in sales of 3 per cent in its financial results for the third quarter of 2011.

The UK-based pharmaceutical company had a turnover of $7.10bn for the period compared to $6.81bn in 2010.

Net profit for GSK remained stationery at $1.49bn, however, as costs related to selling and administration rose.

Vaccines were a particularly strong area of growth for GSK, with revenue in the division increasing by 21 per cent. This was mainly related to sales of Cervarix as part of Japan's national HPV programme.

Total turnover grew 34 per cent in Japan during the quarter, with the strong performance of Avodart following its recent launch also contributing to strong sales in the region.

Emerging markets also saw increased revenue, growing by 11 per cent, helping the company overcome a drop in sales of 5 per cent in Europe and 1 per cent in the US.

26th October 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

robot
AI’s potential in the pharma life cycle
At a time that the future of life sciences is being hotly debated, the opportunity for the industry to refine and expand its role is an important one to take...
OUTiCO Case Study - Product Launch
POSITIVE FORMULARY SUCCESS WITHIN 8 MONTHS!...
An insight into Multi-Channel Account Management
At OUTiCO we often talk about moving away from traditional methods, embracing change, and offering an exceptional outsourcing service, but what does that mean day to day?...

Infographics